The Week in Blood Pressure & Wearables — October 30-November 5, 2026

By Yair Lurie, Founder and CEO, Cardiowell. LinkedIn Newsletter edition, November 6, 2026.

CMS released its final 2027 Medicare Physician Fee Schedule on November 4. It delays the rule that would have limited remote monitoring payments to work done by a practice's own employees, keeps the new initiating-visit requirement, and cuts what Medicare pays for the monitoring device. That's this week's deep dive.

Also this week: two studies tested whether wearables can flag high blood pressure risk early, one from Google Research in Nature and one heading to the American Heart Association meeting. Samsung Health started offering Lark's AI diabetes prevention program to adults 65 and older, Sky Labs published new treatment data for its CART ring, and a blood pressure combination pill was recalled.

Deep dive: CMS finalizes its 2027 remote monitoring rules and gives practices two more years on staffing

What happened

CMS published the calendar year (CY) 2027 Physician Fee Schedule final rule on November 4, with payment policies effective January 1, 2027, per the CMS fact sheet. We've followed the proposed rule since July. More than 44,000 comments were filed, per Prevounce.

Remote physiologic monitoring, or RPM, is how Medicare pays practices to collect readings like blood pressure from patients at home and review them. Remote therapeutic monitoring (RTM) is a similar set of codes for non-physiologic data such as medication compliance.

What CMS finalized

CMS finalized three of its remote monitoring proposals as proposed:

  • An initiating visit. Practitioners billing RPM or RTM "must furnish a separately reportable initiating visit in association with the onset of RPM or RTM services," per CMS.

  • RTM for established patients only.

  • New valuations. CMS finalized "updates to how these services are valued" but didn't include numbers in the fact sheet.

What CMS delayed

The proposal that drew the most pushback would pay for RPM and RTM only when clinical staff employed by the billing practice do the work. CMS is "delaying for two years, to Jan. 1, 2029," that requirement. "This policy will be effective for RPM and RTM services beginning with CY 2029," the fact sheet says.

According to Prevounce's analysis of the final rule:

  • The requirement covers only the clinical staff time codes, 99457, 99458, and 99470.

  • CMS declined to define "direct employee" and committed to guidance before 2029.

  • Contracted clinical staff remain allowed through 2028 under existing incident-to rules.

  • Outside vendors can still supply devices, logistics, onboarding, software, and connectivity.

  • Chronic care management (CCM) and advanced primary care management (APCM) aren't subject to the requirement and can still be outsourced.

CMS also took comments on bundling the RPM and RTM codes into four new HCPCS G-codes. It didn't finalize that and "may consider these comments for future rulemaking."

How the initiating visit works

Prevounce reads the rule this way. The visit applies to patients starting RPM on or after January 1, 2027. It can be in person or by telehealth, and it doesn't have to be about RPM; a routine visit that includes monitoring counts. It's one visit per patient, with no deadline between the visit and the start of monitoring. Patients enrolled before January 1, 2027 are covered.

That's a reasonable rule. A clinician who orders monitoring should have seen the patient. I assume many clinic-led programs already enroll patients this way.

What happens to payment

Prevounce estimates the 2027 national rates (non-APM). These use the proposed rule's payment tables, because CMS hadn't yet published the final Addendum B:

  • Device supply codes (99454 and 99445): $52.11 to $41.11, a 21.1% cut. CMS crosswalked them to the self-measured blood pressure (SMBP) codes.

  • Setup and education (99453): $21.71 to $19.90, an 8.3% cut.

  • Treatment management (99457, 99458, 99470): down 2.3%, only from the conversion factor. CMS withdrew its proposal to remove clinical staff time from these codes.

Prevounce expects another device code cut in 2028 and says the AMA's RUC will review practice expense inputs for all RPM codes in January 2027.

The conversion factor, which sets the dollar value of every service, drops to $32.63 for most physicians, a 2.31% cut from $33.40, per CMS. The July proposal had a 1.68% cut. Medical Economics reports that the main driver is the end of a one-year 2.5% increase, and that Medicare telehealth flexibilities run through December 31, 2027. The same rule replaces the G2211 add-on with a modifier that raises visit payment 16%, or 32% for clinicians in Medicare ACOs.

What I think

The two-year delay is good news for practices of all sizes. Some can't hire a nurse just to review readings, and now they have time to plan.

The direction hasn't changed, though. CMS is paying less for the device and valuing the clinical review. I read that as Medicare saying the review is the service. I agree with that. The device gets the reading to the chart. A nurse, pharmacist or physician looking at it and deciding whether to change the dose is what moves blood pressure.

The device still has to be a medical device. Since its 2021 rule, CMS has required RPM devices to meet FDA's definition of a medical device, per Prevounce. Cardiowell's blood pressure monitor is FDA 510(k) cleared. In general, a 510(k) requires a manufacturer to show the FDA that its device is substantially equivalent to one already legally on the market. For a blood pressure monitor, that typically means clinical validation against a reference method under a recognized standard. That matters more as wearables start to show up in remote monitoring conversations, which is the subject of this week's research section below.

A 21% cut to the device code changes the math for anyone supplying devices and connectivity. I think it will push programs toward lower-cost devices and fewer enrolled patients just to bill the device code. I think the programs that hold up will be the ones where the readings lead to treatment changes and add a CCM component to their workflows.

What clinics should do now?

  • Make the initiating visit part of enrollment for new patients starting January 1.

  • If you use contracted staff for RPM review, you have until 2029. Watch for CMS's definition of "direct employee."

  • Re-run program economics at the lower device rate, and expect another cut in 2028.

  • Document the review and the treatment decisions. That's where both the payment and the audit risk sit, which last week's CCM audit story covered.

Clinical & Research

Two studies test whether wearables can flag high blood pressure risk early

Two studies this week asked a similar question from opposite ends: can wearable data tell a clinician something about blood pressure before a cuff does? One screens apparently healthy people for hypertension. The other tries to predict a hypertensive crisis in people already diagnosed.

Google's smartwatch screen for hypertension. Google Research, with Beth Israel Deaconess Medical Center and Harvard Medical School, described a system called AI-PPG-ACC-HTN on November 5, per the Google Research blog. The paper is in Nature. The full article is paywalled, so the figures below come from Google's post.

How it works matters here. The system uses a consumer smartwatch's optical pulse sensor (PPG) and accelerometer, plus the user's height. It doesn't estimate systolic or diastolic numbers. It gives a probability that the person has a persistent hypertensive state, averaged over several days of wear. The blog doesn't name a watch model.

  • Training: pretrained on 492,347 hours of unlabeled sensor data from 2,109 people.

  • Validation: prospective, at five US sites, in 196 people without known cardiovascular disease and not on blood pressure medication. The reference was 24-hour ambulatory blood pressure monitoring (ABPM).

  • Initial screening: sensitivity 65.8%, specificity 90.0%, positive predictive value (PPV) 80.6%. Office blood pressure had 55.3% sensitivity and 77.8% PPV.

  • Confirmation, in 48 people with elevated office readings: the AI had 78.4% sensitivity, 90.9% specificity, and 96.7% PPV. Repeat office readings: 67.6%, 63.6%, and 86.2%. Multi-day home monitoring: 89.2%, 81.8% and 94.3%.

  • A second signal from the accelerometer: besides motion, it picks up the ballistocardiogram (BCG), the tiny wrist vibrations caused by each heartbeat. The model uses both the optical pulse waveform and the BCG.

  • What the model keyed on: for people the model rated higher risk, the optical pulse waves were narrower, had a slower systolic upstroke and a lower d/a ratio. Their BCG signals showed deeper K waves and wider IJK complexes.

Home monitoring had the highest sensitivity in that confirmation group. That fits the new ISH guidelines, which make standardized home monitoring the primary diagnostic method.

The authors say the system "is not intended to replace standard clinical arm cuffs," is not "a definitive standalone medical diagnosis," and is "early feasibility research." The post says the findings "helped inform the blood pressure trends Health Guardian feature in the Google Health app." It also says the methods are "purely exploratory" and don't indicate any existing or upcoming product feature. I'm reporting both statements as written. No FDA status is mentioned. Health Guardian's blood pressure trends, covered on October 16 and 30, are a wellness feature and "not a prescreener for hypertension," per Google.

The limits: sensitivity of 66% means about a third of people with hypertension weren't flagged. The confirmation comparison had 48 people. The study excluded people on blood pressure medication. Apple's hypertension notifications on Apple Watch, a different approach to the same screening goal, received FDA clearance in September 2025.

Predicting a hypertensive crisis up to three days early. An abstract at the American Heart Association's Scientific Sessions 2026 (Chicago, November 6-9) followed 4,190 adults aged 40 to 85 with stage 2 hypertension at one hospital in Sindh, Pakistan, from January 2025 to January 2026, per the AHA newsroom. The mean age was 62.4, and 46% were women. The lead author is Waleed Razzaq Chaudhry, M.D., of the University of Maryland Capital Region Medical Center. This is an area Cardiowell is actively working on. BTW, I am writing this at the AHA conference in Chicago right now. More to come on that)

The measurement setup is easy to misread from the headline. Blood pressure came from a portable cuff-based monitor that took readings day and night. A wrist-worn device with light-based sensors recorded heart rate and heart rate variability (HRV). Neither brand is named. This isn't a cuffless blood pressure study.

  • The AI looked at 47 characteristics, including nighttime dips, the rise after waking, and HRV. The model isn't described.

  • The authors defined a crisis as a reading above 180/120 mm Hg with acute organ damage. 312 participants had 418 crises.

  • About 32% of people who got an alert had a crisis. 97.4% of people without an alert stayed crisis-free.

  • When physicians adjusted medication within 24 hours of an alert, there were about 61% fewer crises and 45% fewer emergency visits than among people without timely intervention. That comparison wasn't randomized.

  • The strongest signals were no drop in blood pressure during sleep (nearly five times the odds of a crisis) and a morning rise of more than 35 mm Hg over nighttime levels (nearly four times).

It's one hospital in one country, the abstract isn't peer-reviewed, and the release gives no sensitivity, AUC, or funding. The AHA's own release still recommends an automatic upper-arm cuff for home use and says wrist and finger monitors "are not recommended because they give less reliable readings." Paul Sonnier shared the study in his Digital Health group on LinkedIn, which is where I first saw it.

What I take from both. The strongest predictors in the AHA study were nighttime and morning patterns. You only see those with frequent readings outside the clinic. The Google study found home monitoring was the most sensitive way to confirm hypertension. Both point to more home measurement.

The AHA result also depends on someone acting within 24 hours. An alert is only useful if a clinician reviews it and changes treatment. That's the same review work CMS just said it values, in the deep dive above. I think wearables will become a useful way to decide who needs a cuff and who needs a call. For now, the cuff still confirms the diagnosis.

Medtronic reports real-world renal denervation results

Medtronic presented six-month results from SPYRAL AFFIRM, a single-arm post-approval study of its Symplicity renal denervation procedure, at TCT 2026, per Medtronic. Office systolic pressure fell 18.2 mmHg, 24-hour ambulatory 9.7 mmHg, and home 9.4 mmHg, with the number of medications unchanged at 3.6. The composite safety endpoint occurred in 2.1% of patients. FDA approved updated labeling adding data for isolated systolic hypertension, chronic kidney disease to stage 3b, and type 2 diabetes.

It's a company release about a study with no control arm, and it doesn't report the number of patients. The gap between the office drop and the home and ambulatory drops is worth noting. Home readings are part of how this procedure's results get reported.

Intensive blood pressure lowering helped people with and without kidney disease

A JAMA Cardiology meta-analysis of 27 randomized trials and about 88,800 people found intensive blood pressure lowering prevented about 4 cardiovascular events per 1,000 person-years in people with chronic kidney disease and about 3 in those without, per JAMA. It didn't change kidney failure rates but was linked to more sustained declines in kidney function at milder thresholds. The authors say guidelines should consider intensive targets regardless of kidney disease status, with kidney monitoring.

Telemedicine was as safe as in-person care for first cardiology visits

A Kaiser Permanente Northern California study in JAMA Network Open looked at 5,735 adults with a first-time cardiology referral for undiagnosed symptoms between 2020 and 2022, per Kaiser Permanente. The 4,064 who chose telemedicine had fewer follow-up cardiology visits, a similar time to diagnosis, and no higher 30-day emergency or hospital rates. It's observational, patients chose their visit type, and senior author Mary Reed said the results don't necessarily generalize outside KP.

Potassium supplements lowered clinic blood pressure, but not ambulatory readings

A Journal of the American Heart Association meta-analysis looked at oral potassium supplements in untreated primary hypertension, per JAHA. The journal page didn't load for me. In the preprint version, 19 small trials with 803 adults showed clinic blood pressure fell 7.2/4.0 mmHg, while 24-hour ambulatory readings fell 2.4/1.6 mmHg, a non-significant change. Results varied widely between trials. The authors recommend confirming any response with out-of-office readings.

High blood pressure before pregnancy was linked to fetal heart defects

An AHA abstract using more than 44 million US births from 2018 to 2024 found chronic hypertension before pregnancy was linked to about 30% higher risk of critical congenital heart disease, and pre-existing diabetes to about 48%, per EurekAlert!. It's observational birth-certificate data with no information on blood pressure control, and the absolute risk is low.

Devices & Wearables

Samsung Health brings Lark's AI diabetes prevention program to adults 65 and older

Samsung announced on October 26 that Samsung Health users 65 and older can get AI-driven prevention support through Lark Health, per the Samsung Newsroom. This predates our window, and we didn't cover it last week.

  • First phase: Lark's Medicare Diabetes Prevention Program for eligible users, meaning Medicare Part B and no active diabetes diagnosis. It includes 24/7 AI coaching on nutrition, activity, sleep, and stress, live clinical resources, and a cellular scale.

  • Others: users who don't qualify may get Lark Prevention, listed at $249 a year, at no added cost "for the duration of this agreement."

  • Next: a planned rollout through CMS's ACCESS Model for cardiometabolic and behavioral health programs. Details will come as each program launches. No hypertension program is named yet.

The release doesn't mention FDA. The "2.5 million patients" figure is Lark's own, with no outcome data. Samsung's Hon Pak said, "care has to move beyond the clinic and into people's everyday lives."

Rudolf Wagner made a regulatory point on LinkedIn. In the US, lifestyle programs that reduce chronic disease risk fall under FDA's January 2026 general wellness policy. The EU's medical device definition starts with "diagnosis, prevention," so a program built to prevent a specific disease would at least have to be examined there. He doesn't claim the product is unsafe or non-compliant.

I'll watch the ACCESS angle. ACCESS includes cardiometabolic tracks, and if Lark adds hypertension, Samsung users could get blood pressure coaching through their phone at no added cost.

Sky Labs reports CART-guided treatment data and says its ring is in Korea's guidelines

A Korea University Anam Hospital study in Clinical Hypertension followed 246 patients with uncontrolled hypertension for six months, Dailypharm reports. Treatment for 67 was guided by 24-hour readings from Sky Labs' CART ring; 179 had usual care. Among 162 patients with complete 24-hour data at six months, 65.8% of the CART group reached target versus 36.3% with usual care, and adjusted 24-hour systolic was 7.35 mmHg lower. The CART group added more drug classes (0.85 vs. 0.37). The study wasn't randomized; the comparison used a subset, and the authors say a randomized trial is needed.

Sky Labs posted on LinkedIn that it is presenting CART BP pro, "now listed in the KSH guidelines," at Hypertension Seoul 2026 (November 5-7), with a lunch symposium today on cuffless monitoring "from validation to real clinical practice," featuring George Stergiou and Hyung Joon Joo. I haven't checked the Korean Society of Hypertension guideline text for how CART is listed. Sky Labs is also exhibiting at MEDICA 2026 in Düsseldorf, November 16-19.

CART BP pro is a finger ring with an optical sensor, calibrated with a cuff. It's approved and reimbursed in Korea, CE-marked, and UK MHRA-registered, and isn't FDA-authorized, per Korea Biomedical Review. The study is useful because it measures what changed in treatment, which is the point of any monitor.

PulseAI gets FDA 510(k) clearance for a smartwatch arrhythmia model

PulseAI received FDA 510(k) clearance for a cloud-based AI model that analyzes smartwatch ECG recordings for atrial fibrillation, per PulseAI's release. It claims 92% fewer inconclusive readings than Apple Watch's built-in algorithm, citing a 296-person study in Heart Rhythm. The release doesn't name compatible watches. Inconclusive readings are a real cost in remote monitoring because someone has to review each one.

StimCardio raises $30 million for a wrist device to treat atrial fibrillation

StimCardio raised a $30 million Series A led by Metis Medtech for Rhyvive, a wrist device with ECG and optical sensors that stimulates the median nerve to reduce atrial fibrillation recurrence after ablation, per HLTH. It's investigational. The money funds a pivotal trial, and a De Novo submission is in preparation. There's no efficacy data yet.

A year of Fitbit data found more health links than a single day

Oxford researchers analyzed Fitbit data from about 29,000 All of Us participants with linked health records, per Oxford Population Health. In the preprint, a one-year average step count was linked to 373 existing and 37 new conditions, versus 231 and 17 for a single day, and step counts became reliable after about 58 days of wear. It's observational; 69% of participants were women, and hypertension isn't singled out. Long-term averages beat single snapshots, the same lesson as with home blood pressure.

Policy & Regulation

A blood pressure combination pill is recalled for failing a dissolution test

Macleods Pharma USA recalled two lots of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets after they failed dissolution specifications, meaning the pills may not dissolve and work as intended, FOX Television Stations reports. The recall covers 3,528 30-count and 216 90-count bottles from lots 12251163A and 12251163B, both expiring May 31, 2027. Macleods started the recall on October 7, and the FDA classified it as Class II on October 26. Patients shouldn't stop medication on their own; they should check the lot number with their pharmacist.

A pill that doesn't dissolve shows up as blood pressure that stops responding. Home readings are one way a clinic would notice.

A Senate draft would set FDA and Medicare rules for health AI

Senate HELP Committee Chairman Bill Cassidy released a discussion draft of the PATIENT AI Act on October 29, per the committee. According to Medical Daily:

  • It sorts AI tools between FDA and ONC oversight, lets FDA review software changes on a rolling basis, and allows certified third parties to review low- to moderate-risk software.

  • Medicare would build coverage, payment and billing codes for AI-based services, and couldn't deny value "solely because" no physician interprets results at the same time.

  • CMMI would test a five-year payment model for AI that performs a clinical function on its own. "Autonomously" isn't defined.

Comments are due December 1. It's a discussion draft and hasn't been introduced as a bill. Blythe Karow covered the draft in The Device Files this week and noted that at AdvaMed, CMS officials said they couldn't yet talk about new coverage for wearables. The AMA also released a framework on AI liability on October 29, which says physicians shouldn't carry all the liability for AI tools they can't meaningfully assess. Christina Farr summarized it in Second Opinion.

For blood pressure, the payment piece matters most. Alerts like the ones in this week's AHA study would need a payment path to reach clinics.

Also worth a glance

  • RPM and CCM nurses in one model. Healthcare IT News reports that ARCare, a community health center in Arkansas, connected its RPM work to the care management nurses it already had. The page didn't load for me, so I couldn't confirm the "triples nurse capacity" figure. It's the kind of in-house model the 2029 staffing rule points toward.

  • Medically tailored meals. An AHA abstract found 110 New York City adults with type 2 diabetes and hypertension lowered systolic and diastolic pressure about 4 mmHg each over eight months on medically tailored meals, per the AHA. Single site, no no-meal control group.

  • Potassium in guidelines. An expert report in the American Journal of Clinical Nutrition argues blood pressure guidelines should give potassium equal weight with sodium, including potassium salt substitutes with caution in kidney disease, per ScienceDaily. An industry-funded group supported the committee.

  • Diet and heart rate variability. In 7,256 adults in the Maastricht Study with 24-hour Holter ECG, DASH diet adherence wasn't linked to standard HRV measures after adjustment, only to one debated frequency band, per News-Medical.

  • WHOOP at Ulta Beauty. WHOOP 5.0 and MG go on sale at Ulta in March 2027, per HLTH. WHOOP's "Blood Pressure Insights" feature is listed without a regulatory status.

  • After the midterms. Second Opinion's panel discussed what Democratic control of both chambers could mean for health policy, including possible ACA subsidy changes. There were no remote monitoring specifics.

The thread this week

This week was about what happens after the reading.

CMS cut what it pays for the device and protected the clinical review. The AHA study found alerts helped when a physician acted within 24 hours. Google's screening study found home monitoring was the most sensitive way to confirm a diagnosis. Sky Labs' data measured how often treatment changed. Even the recall is a case where home readings would show the problem first.

I'm optimistic. Wearables are getting better at telling us who needs attention, and Medicare is starting to pay for the attention itself. The work for clinics in 2027 is making that review routine.

This edition is also published on the Cardiowell blog: [ARTICLE URL — cardiowell.com, not yet published]

We update our blood wearable blood pressure registry list regularly. See our latest updates here: https://www.cardiowell.com/wearable-bp-registry

If a colleague forwarded this to you, subscribe to The Week in Blood Pressure & Wearables to get it every Friday.

References

  1. Calendar Year (CY) 2027 Medicare Physician Fee Schedule Final Rule. Centers for Medicare & Medicaid Services.

  2. The Pushback on CMS's Proposed 2027 Changes to RPM. Prevounce.

  3. 2027 Physician Fee Schedule Final Rule: What's Changing for RPM, What Isn't, and What Could Still Change. Prevounce.

  4. Medicare's final 2027 fee schedule cuts physician pay more than proposed but softens the same-day visit penalty. Medical Economics.

  5. Understanding Medicare's Changes to Remote Patient Monitoring for 2021. Prevounce.

  6. Detecting signs of hypertension using wearable sensors. Google Research.

  7. Google Research and BIDMC smartwatch hypertension study, article s41586-026-11336-3 (paywalled; title not confirmed). Nature.

  8. Google Research on LinkedIn: a new system for detecting signs of hypertension with wearable sensors. Google Research on LinkedIn.

  9. Apple receives FDA nod for hypertension notification feature. HLTH.

  10. Wearable devices + AI analysis may predict high blood pressure crisis up to 3 days early. American Heart Association Newsroom.

  11. Paul Sonnier on LinkedIn: wearables and AI to predict a hypertensive crisis. Paul Sonnier on LinkedIn (Digital Health group).

  12. TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study. Medtronic.

  13. Intensive BP Lowering Reduces Cardiovascular Risk in Adults With CKD. JAMA.

  14. Telemedicine is safe option for first-time cardiology visits. Kaiser Permanente Division of Research.

  15. Oral potassium supplementation and clinic blood pressure in untreated primary hypertension (meta-analysis). Journal of the American Heart Association.

  16. Hypertension or diabetes before pregnancy linked to higher risk of fetal heart defects. EurekAlert! (American Heart Association).

  17. Samsung Health Expands AI-Powered Diabetes Prevention and Chronic Condition Support for Older Adults Through Lark Health. Samsung Newsroom.

  18. Samsung will now coach Americans over 65 to avoid diabetes. With AI.. Rudolf Wagner on LinkedIn.

  19. 스카이랩스 카트 활용군, 목표 혈압 도달률 65.8% 기록 (Sky Labs CART group reaches 65.8% target blood pressure attainment). Dailypharm.

  20. We're exhibiting at Hypertension Seoul 2026!. Sky Labs on LinkedIn.

  21. We're exhibiting at MEDICA 2026 in Düsseldorf!. Sky Labs on LinkedIn.

  22. Sky Labs eyes UK healthcare market with ring-type CART BP monitor. Korea Biomedical Review.

  23. PulseAI Receives U.S. FDA 510(k) Clearance of AI-Powered Arrhythmia Analysis Model for Wearables. PR Newswire.

  24. StimCardio Raises $30M to Advance Wearable Atrial Fibrillation Therapy. HLTH.

  25. New study shows the value of long-term wearable data. Oxford Population Health.

  26. Preprint: long-term Fitbit data and health conditions in the All of Us Research Program (PMC12870592). medRxiv via PubMed Central.

  27. Thousands of blood pressure medication bottles recalled nationwide after pills fail quality test. FOX 5 DC (FOX Television Stations).

  28. Chairman Cassidy Unveils Discussion Draft to Expand Access to AI in Health Care, Improve Care for Patients. U.S. Senate HELP Committee.

  29. Medicare Could Test Paying for AI That Performs Clinical Tasks on Its Own Under Cassidy's Senate Draft. Medical Daily.

  30. AI Autonomy in Medical Devices: When KITT Takes the Wheel. The Device Files (Blythe Karow).

  31. AMA framework on liability and clinical AI. American Medical Association.

  32. Who is liable for AI mistakes. Second Opinion (Christina Farr).

  33. ARCare triples nurse capacity by combining RPM and chronic care management. Healthcare IT News.

  34. Medically tailored meals improved high blood pressure, Type 2 diabetes and diet in adults. American Heart Association Newsroom.

  35. Experts say high blood pressure guidelines are missing half the equation. ScienceDaily.

  36. Two healthy diets stood out in a study of more than 7,000 adults. News-Medical.

  37. WHOOP and Ulta Beauty Announce Retail Partnership to Expand Access to Wearable Health Technology. HLTH.

  38. Decoding what the blue tsunami means for health care. Second Opinion (Christina Farr).

Previous
Previous

The Week in Blood Pressure & Wearables — November 6-12, 2026

Next
Next

The Week in Blood Pressure & Wearables — October 23-29, 2026